Laquinimod
- Generic Name
- Laquinimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17ClN2O3
- CAS Number
- 248281-84-7
- Unique Ingredient Identifier
- 908SY76S4G
- Background
Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally.
- Indication
Investigated for use/treatment in multiple sclerosis.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Laquinimod Eye-drops in Healthy Participants
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 54
- Registration Number
- NCT05187403
- Locations
- 🇦🇹
Clinical trial center at Medical University Vienna, Vienna, Austria
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
- Conditions
- Interventions
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT02284568
- Locations
- 🇩🇪
Teva Investigational Site 32512, Bamberg, Germany
🇩🇪Teva Investigational Site 32505, Bad Mergentheim, Germany
🇩🇪Teva Investigational Site 32523, Trier, Germany
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 352
- Registration Number
- NCT02215616
- Locations
- 🇨🇦
Teva Investigational Site 11079, Toronto, Ontario, Canada
🇺🇸Teva Investigational Site 12567, San Francisco, California, United States
🇺🇸Teva Investigational Site 12565, Los Angeles, California, United States
A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together
- Conditions
- Interventions
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02085863
- Locations
- 🇩🇪
Teva Investigational Site 32415, Moenchengladbach, Germany
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT01975298
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 2199
- Registration Number
- NCT01707992
- Locations
- 🇺🇸
Teva Investigational Site 10315, Sunrise, Florida, United States
🇺🇸Teva Investigational Site 10342, Tucson, Arizona, United States
🇺🇸Teva Investigational Site 10341, Saint Petersburg, Florida, United States
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT01085084
- Locations
- 🇺🇸
Teva Investigational Site 1366, Charleston, South Carolina, United States
🇺🇸Teva Investigational Site 1369, Bronx, New York, United States
🇨🇦Teva Investigational Site 1142, Montreal, Quebec, Canada
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT01085097
- Locations
- 🇺🇸
Teva Investigational Site 1022, Lake Success, New York, United States
🇬🇧Teva Investigational Site 3412, Dudley, United Kingdom
🇨🇦Teva Investigational Site 1114, Winnipeg, Manitoba, Canada
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1047
- Registration Number
- NCT01047319
- Locations
- 🇺🇸
Teva Investigational Site 1267, Homewood, Alabama, United States
🇺🇸Teva Investigational Site 1275, Atlanta, Georgia, United States
🇺🇸Teva Investigational Site 1272, Pasadena, California, United States
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 839
- Registration Number
- NCT00988052
- Locations
- 🇧🇬
Teva Investigational Site 5904, Sofia, Bulgaria
🇨🇦Teva Investigational Site 1132, Bedford, Nova Scotia, Canada
🇬🇪Teva Investigational Site 8100, Tbilisi, Georgia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.